Fatty acid oxidation disorders, Annu. Rev. Physiol, vol.64, pp.477-502, 2002. ,
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency, Am. J. Hum. Genet, vol.64, pp.479-494, 1999. ,
Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship, Hum. Mutat, vol.18, pp.169-189, 2001. ,
Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Molecular pathogenesis and genotype-phenotype relationships, Eur. J. Biochem, vol.271, pp.470-482, 2004. ,
Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients, Clin. Chim. Acta, vol.269, pp.43-62, 1998. ,
Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.23, pp.27-44, 2000. ,
Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders, Clin. Chim. Acta, vol.323, pp.37-58, 2002. ,
Application of tandem mass spectrometry to biochemical genetics and newborn screening, Clin. Chim. Acta, vol.322, pp.1-10, 2002. ,
MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency, J Pediatr, vol.143, pp.335-342, 2003. ,
Recognition and management of fatty acid oxidation defects: a series of 107 patients, J. Inherit. Metab. Dis, vol.22, pp.488-502, 1999. ,
Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride, J. Clin. Invest, vol.110, pp.259-269, 2002. ,
Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, vol.144, pp.2201-2207, 2003. ,
The mechanisms of action of PPARs, Annu. Rev. Med, vol.53, pp.409-435, 2002. ,
Medical significance of peroxisome proliferator-activated receptors, Lancet, vol.354, pp.141-148, 1999. ,
PPARs and the complex journey to obesity, Nat. Med, vol.10, pp.355-361, 2004. ,
Recent developments in the investigations of inherited metabolic disorders using cultured human cells, Mol. Genet. Metab, vol.68, pp.243-257, 1999. ,
Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid beta-oxidation defects: phenotype/metabolite correlations, Mol. Genet. Metab, vol.76, pp.327-334, 2002. ,
Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA, Biochem. Biophys. Res. Commun, vol.157, pp.1148-1153, 1988. ,
Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha), J. Biol. Chem, vol.273, pp.5678-5684, 1998. ,
Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice, Biochim. Biophys. Acta, vol.1632, pp.80-89, 2003. ,
Characterization of the bidirectional promoter region between the human genes encoding VLCAD and PSD-95, Genomics, vol.82, pp.660-668, 2003. ,
Correction of fatty acid oxidation in carnitine palmitoyl transferase II-deficient cultured skin fibroblasts by bezafibrate, Pediatr. Res, vol.54, pp.446-451, 2003. ,
10-3H]myristic acids for the detection of defects of fatty acid oxidation in intact cultured fibroblasts, J. Inherit. Metab. Dis, vol.9, pp.58-68, 1990. ,
Disorders of mitochondrial fatty acyl-CoA beta-oxidation, J. Inherit. Metab. Dis, vol.22, pp.442-487, 1999. ,
Peroxisome proliferator activated receptor d (PPARd) agonist but not PPARa corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells, J. Clin. Endocrinol. Metab, vol.90, pp.1791-1797, 2005. ,